Edition:
United States

United Therapeutics Corp (UTHR.OQ)

UTHR.OQ on NASDAQ Stock Exchange Global Select Market

119.08USD
26 May 2017
Change (% chg)

$0.74 (+0.63%)
Prev Close
$118.34
Open
$118.74
Day's High
$120.37
Day's Low
$118.67
Volume
230,059
Avg. Vol
240,490
52-wk High
$169.58
52-wk Low
$97.70

Latest Key Developments (Source: Significant Developments)

United Therapeutics says it entered into first amendment to license agreement with Eli Lilly and company
Thursday, 18 May 2017 06:07am EDT 

May 18 (Reuters) - United Therapeutics Corp :United Therapeutics Corp - on May 17, 2017, co entered into first amendment to license agreement with Eli Lilly and company.United therapeutics - amendment to clarify and extend term of agreement and to amend economic terms of agreement following a patent expiry in nov 2017.  Full Article

United Therapeutics and 3D Systems announce bioprinting agreement
Wednesday, 26 Apr 2017 06:00am EDT 

April 26 (Reuters) - 3d Systems Corp :United therapeutics corp- 3d systems,united therapeutics today announced plans to develop solid-organ scaffolds for human transplants.  Full Article

Respira Therapeutics says entered into strategic collaboration with United Therapeutics
Wednesday, 12 Apr 2017 09:45am EDT 

Respira Therapeutics : Respira Therapeutics says entered into a strategic collaboration with united therapeutics corporation for development and exclusive license of respira's rt234 . In addition, United Therapeutics will be lead investor in respira's series B preferred stock financing . As per collaboration, United Therapeutics will provide co with non-dilutive development funding to advance rt234 through fda approval . Additional terms of strategic collaboration were not disclosed .To continue advancing development of other pipeline programs,to retain full control of research and development programs outside of pulmonary hypertension.  Full Article

United Therapeutics announces regulatory delays for Remosynch Implantable Pump
Monday, 3 Apr 2017 06:00am EDT 

United Therapeutics Corp : United Therapeutics-regulatory delays will result in postponement of planned U.S. launch of remosynch implantable system for remodulin until 2018 .United therapeutics - in order to launch remosynch in U.S, medtronic and co have been pursuing parallel regulatory filings relating to device and drug.  Full Article

United Therapeutics says Patent Trial and Appeal Board found that all claims of '393 patent are not patentable
Friday, 31 Mar 2017 01:15pm EDT 

United Therapeutics Corp : United Therapeutics announces decision from patent trial and appeal board and issuance of new patents . Patent Trial and Appeal Board found that all claims of '393 patent are not patentable . '393 patent remains valid and enforceable until appeals have been exhausted . Evaluating options including exercising right of appeal to U.S. Court of Appeals or first requesting a rehearing before PTAB .Anticipates related patents; U.S. Patent Nos. 9,593,066 and 9,604,901, should be less susceptible to challenge than '393 patent.  Full Article

United Therapeutics, Northwell Health's Feinstein Institute announce partnership
Thursday, 9 Mar 2017 06:00am EST 

United Therapeutics Corp : United Therapeutics - co, Northwell Health's Feinstein Institute for Medical Research announced strategic partnership . United Therapeutics Corp - under partnership, united therapeutics will fund Northwell's efforts in four research and development tracks .United Therapeutics -partnership for application of bioelectronic medicine, cell therapy to cardiology, hypertension, post-transplant tolerance induction.  Full Article

United Therapeutics reports Q4 non-GAAP eps of $4.12
Wednesday, 22 Feb 2017 06:00am EST 

United Therapeutics Corp : United Therapeutics Corporation reports 2016 fourth quarter and annual financial results . Q4 revenue $409 million . Q4 revenue view $415.5 million -- Thomson Reuters I/B/E/S . Qtrly earnings per share $2.43 . Qtrly non-GAAP earnings per share $4.12 .Q4 earnings per share view $3.61 -- Thomson Reuters I/B/E/S.  Full Article

United Therapeutics reports Q3 EPS $3.50
Thursday, 27 Oct 2016 06:00am EDT 

United Therapeutics Corp : United therapeutics corporation reports third quarter 2016 financial results . United therapeutics corp - qtrly earnings per share $ 3.50 . United therapeutics corp - qtrly adjusted earnings per share $ 4.36 . Qtrly non-gaap earnings, per diluted share $ 4.36 . United therapeutics corp - qtrly revenues $ 408.2 million versus. $ 386.2 million .Q3 earnings per share view $3.34, revenue view $402.4 million -- Thomson Reuters I/B/E/S.  Full Article

United Therapeutics Corp Q2 income per diluted share $4.39
Thursday, 28 Jul 2016 06:00am EDT 

United Therapeutics Corp Qtrly Non : United Therapeutics Corp qtrly net income, per diluted share $4.39 . Q2 earnings per share view $3.22, revenue view $395.0 million -- Thomson Reuters I/B/E/S . United Therapeutics Corporation reports second quarter 2016 financial results . Q2 revenue $400 million versus I/B/E/S view $395 million .Gaap earnings, per diluted share $4.55.  Full Article

United Therapeutics Corp says Roger Jeffs steps down as president and co-CEO
Thursday, 28 Apr 2016 06:31am EDT 

United Therapeutics Corp:Says Roger Jeffs steps down as president and co-chief executive officer.Says David Zaccardelli steps down as executive vice president and chief operating officer.United Therapeutics Corp says David Zaccardelli, steps down as executive vice president and chief operating officer.United Therapeutics Corp says Michael Benkowitz promoted to president and chief operating officer.United Therapeutics Corp says Martine Rothblatt, remains chairman of board and becomes sole chief executive officer.Says Michael Benkowitz promoted to president and chief operating officer.United therapeutics corp says Jeffs will become a senior advisor to company.  Full Article

More From Around the Web

BRIEF-United Therapeutics says it entered into first amendment to license agreement with Eli Lilly and company

* United Therapeutics Corp - on May 17, 2017, co entered into first amendment to license agreement with Eli Lilly and company